bromocriptine has been researched along with estradiol 3-benzoate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Goyeneche, AA; Telleria, CM | 1 |
| Chen, Y; Wang, A; Wang, S; Wang, X; Wu, J; Zhang, Y; Zhu, K | 1 |
3 other study(ies) available for bromocriptine and estradiol 3-benzoate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Exogenous estradiol enhances apoptosis in regressing post-partum rat corpora lutea possibly mediated by prolactin.
Topics: Androstenedione; Animals; Apoptosis; Bromocriptine; DNA Fragmentation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Luteolysis; Parturition; Pregnancy; Progesterone; Prolactin; Rats; Rats, Sprague-Dawley | 2005 |
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Topics: Animals; Apoptosis; Bromocriptine; Cell Line, Tumor; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Estradiol; Female; Gene Expression Regulation; Mitogen-Activated Protein Kinase 11; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinase 13; Mitogen-Activated Protein Kinase 14; p38 Mitogen-Activated Protein Kinases; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Signal Transduction | 2021 |